Cinclus Pharma Holding AB (publ) (STO:CINPHA)

Sweden flag Sweden · Delayed Price · Currency is SEK
15.60
+0.16 (1.04%)
At close: Aug 29, 2025
1.04%
Market Cap725.99M
Revenue (ttm)38.68M
Net Income (ttm)-172.93M
Shares Out46.54M
EPS (ttm)-4.14
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume71,628
Average Volume47,031
Open15.78
Previous Close15.44
Day's Range15.32 - 15.96
52-Week Range9.31 - 31.30
Betan/a
RSI41.68
Earnings DateAug 20, 2025

About Cinclus Pharma Holding AB

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company’s lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and... [Read more]

Sector Healthcare
Founded 2014
Employees 18
Stock Exchange Nasdaq Stockholm
Ticker Symbol CINPHA
Full Company Profile

Financial Performance

In 2024, Cinclus Pharma Holding AB's revenue was 4.58 million, a decrease of -23.14% compared to the previous year's 5.96 million. Losses were -168.03 million, -21.89% less than in 2023.

Financial Statements

News

There is no news available yet.